The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

VIJAYAWADA: Sickle cell anaemia and thalassemia remain major health concerns in the State, particularly among tribal ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...

According to research studies and demographic surveys by the Union Ministry of Tribal Affairs and genetic researchers, sickle cell disease is widespread in many tribal groups of India, especially amon ...

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...

The therapy – which is based on CD34+ stem cells taken from patients that are modified to carry a working gene for beta-globin, a haemoglobin component that is deficient in thalassemia patients ...

researchers in China surprised everyone by announcing that they had used CRISPR in nonviable human embryos to try to fix the genetic defect that causes beta-thalassemia, a potentially fatal blood ...